Beta Bionics (BBNX) FCF Margin (2024 - 2026)

Beta Bionics (BBNX) posted FCF Margin of 48.92% for Q2 2026, up 46.39% sequentially from 91.25% in Q1 2026, and up 1723.0% YoY from 2.68% in Q2 2025.

Beta Bionics (BBNX) FCF Margin (2024 - 2026) Analysis & Trends

Beta Bionics has reported FCF Margin for 3 years, with the latest figure at 48.92% in Q2 2026.

Quarterly FCF Margin rose 1723.0% year-over-year to 48.92% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 51.6% (up 2788.0% YoY) and the FY2025 annual result came in at 56.08%, up 2326.0% from the prior year.
FCF Margin climbed to 48.92% in Q2 2026 per BBNX's latest filing, from 91.25% in the prior quarter.
Over five years, FCF Margin peaked at 32.78% in Q4 2025 and troughed at 115.13% in Q1 2025.
A 3-year average of 71.44% and a median of 70.7% in 2024 frame the typical range for FCF Margin.
The widest YoY moves for FCF Margin: up 3982 bps in 2025, down 1809 bps in 2025.
Over 3 years, FCF Margin stood at 72.6% in 2024, then soared by 55 bps to 32.78% in 2025, then tumbled by 49 bps to 48.92% in 2026.
According to Business Quant data, FCF Margin over the past three periods registered 48.92%, 91.25%, and 32.78% for Q2 2026, Q1 2026, and Q4 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Abbott Laboratories	201.82 Bn	196.22 Bn	7.27 Bn	15.81%
2	Stryker	127.00 Bn	123.52 Bn	4.50 Bn	16.07%
3	Medtronic	118.94 Bn	109.72 Bn	6.41 Bn	21.26%
4	Boston Scientific	74.26 Bn	73.72 Bn	3.85 Bn	23.50%
5	Edwards Lifesciences	51.61 Bn	47.36 Bn	1.35 Bn	33.60%
6	Dexcom	35.00 Bn	33.05 Bn	830.00 Mn	14.10%
7	GE HealthCare Technologies	33.71 Bn	31.60 Bn	2.18 Bn	1.28%
8	Koninklijke Philips	26.25 Bn	22.93 Bn	4.55 Bn	5.32%
9	Steris	23.16 Bn	22.68 Bn	684.20 Mn	18.73%
10	Beta Bionics	859.28 Mn	678.79 Mn	18.90 Mn	-48.92%

Download Data